Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Water Main Break Advisory
We are open for business and taking extra preventative measures to keep you safe. Read more ❱❱

2017

Evidence review supports pediatric use of PDE 5 inhibitors for pulmonary hypertension

A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published Feb. 24, 2017 in Pediatrics demonstrates that scientific evidence supports the use of this class of medications in infants, neonates and children with pulmonary hypertension.

Newborn genetics

Children’s National Announces the Creation of First-of-its-Kind Rare Disease Institute

Children's National Health System, the nation’s largest provider of care for children with rare genetic disorders, announced it has formed the Children’s National Rare Disease Institute (CNRDI), a first-of-its-kind center focused exclusively on advancing the care and treatment of children and adults with rare genetic diseases.